💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
RPG Life Sciences Limited is an India-based research-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, stagnant business, priced for perfection.
RPG Life Sciences is scored on the pharma / healthcare framework. It keeps a healthy 15.7% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.49×) — worth a closer look. Free cash flow is worth about 3.4% of its market value.
Over the last 1 years revenue compounded at 10%/yr and profit at -37%/yr. Book value has grown 14%/yr. Return on equity is a healthy 15.9%. In the latest quarter profit fell 8% versus the prior quarter.
At 37× earnings, the stock sits at the 81st percentile of its own 1.6-year range — the expensive end of where it has historically traded. Today's price implies ~18%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 38.15 | — | — |
| P/B | 6.15 | 4.11 | worse |
| EV/EBITDA | 24.15 | 19.15 | worse |
| ROE | 15.89 | — | — |
| ROCE | 20.87 | 6.87 | better |
| ROA | 9.93 | — | — |
| Quick Ratio | 2.71 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 2 financial years shown. 10% CAGR over 1 years — steady double-digit compounder.
Revenue is outpacing profit (10% vs -37%) — costs are rising faster than the top line. The latest year saw a -37% swing — check if it's a one-off or structural.
Operating margin has compressed from 35% to 21% — costs or competition are eating into profitability. Interest or tax burden is shrinking — more of the operating profit is reaching the bottom line.
ROE at 19% — a respectable return on shareholder capital. Capital efficiency declining — ROE down 16pp.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -37% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 0.5× PAT — reported profit isn't translating into cash, raising earnings quality questions. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 8% sequentially — momentum is building. Run-rate stepping up — recent quarters average 12% above earlier ones.
How today's P/E compares to the stock's own historical range. Dashed line = the 1.6y median.
Promoters hold 73.0% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.